Sign in

Private company

Augmedix, Inc.

Augmedix, Inc. is an American business services company that raised $12 million in 2023 (SEC Form D).1 It is headquartered in San Francisco, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryServices-Business Services, NEC1
  • HeadquartersSan Francisco, California1
  • Incorporated inDE2
  • Business address111 Sutter Street, Suite 1300, San Francisco, Ca 941042
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Augmedix empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust. Our platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decision support.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

48.0%Gross margin4
-41.9%Operating margin4
-42.7%Net margin4
45.0%Revenue growth, 20234
-82.2%Return on equity4
-$18.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue52¢$23.3M
  • Research and development25¢$11.2M
  • Other costs23¢$10.2M
  • Income tax0¢$145.0K

Out of $44.9M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$44.9M in 2023+218% since 2019
0$20.0M$40.0M$60.0M2019: $14.1M$14.1M20192020: $16.5M$16.5M2020+17%2021: $22.2M$22.2M2021+34%2022: $30.9M$30.9M2022+40%2023: $44.9M$44.9M2023+45%
Gross profit5674$21.5M in 2023+360% since 2019
0$10.0M$20.0M$30.0M2019: $4.7M$4.7M20192020: $6.8M$6.8M2020+45%2021: $10.0M$10.0M2021+47%2022: $14.0M$14.0M2022+39%2023: $21.5M$21.5M2023+54%
Operating income5674-$18.8M in 2023+12% since 2019
-$30.0M-$20.0M-$10.0M02019: -$16.7M-$16.7M20192020: -$13.7M-$13.7M2020−18%2021: -$17.6M-$17.6M2021+28%2022: -$22.4M-$22.4M2022+27%2023: -$18.8M-$18.8M2023−16%
Net income5674-$19.2M in 2023+4% since 2019
-$30.0M-$20.0M-$10.0M02019: -$18.5M-$18.5M20192020: -$15.6M-$15.6M2020−16%2021: -$17.5M-$17.5M2021+12%2022: -$24.4M-$24.4M2022+40%2023: -$19.2M-$19.2M2023−22%
Fiscal year201820192020202120222023
Revenue$14.1M5$16.5M6$22.2M7$30.9M4$44.9M4
Cost of revenue$9.4M5$9.7M6$12.2M7$17.0M7$23.3M4
Gross profit$4.7M5$6.8M6$10.0M7$14.0M4$21.5M4
Research and development$7.0M5$4.5M6$6.7M7$10.1M4$11.2M4
Operating expenses$27.6M7$36.3M4$40.3M4
Operating income-$16.7M5-$13.7M6-$17.6M7-$22.4M4-$18.8M4
Interest$3.1K10
Income before tax-$17.4M7-$24.3M4-$19.0M4
Income tax$47.0K7$111.0K4$145.0K4
Net income-$18.5M5-$15.6M6-$17.5M7-$24.4M4-$19.2M4
Earnings per share-$0.607-$0.654-$0.444
Earnings per share (diluted)-$0.607-$0.654-$0.444
Shares (weighted, basic)28.9M shares737.4M shares443.9M shares4
Shares (weighted, diluted)28.9M shares737.4M shares443.9M shares4

Compare Augmedix, Inc. with another company

Corporate structure

Augmedix, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Augmedix, Inc.

  • Beryl Capital Management LLC Filed SC 13G/A on Augmedix, Inc., latest Nov 13, 2024 (2 filings since Jul 29, 2024)
  • Samjo Management, LLC Filed SC 13G/A on Augmedix, Inc., latest Nov 13, 2024 (3 filings since Feb 9, 2024)
  • Redmile Group, LLC Filed SC 13D/A on Augmedix, Inc., latest Oct 4, 2024 (8 filings since Nov 1, 2021)
  • DCM VI, L.P. Filed SC 13D/A on Augmedix, Inc., latest Feb 26, 2024 (7 filings since Nov 12, 2021)
  • Mark N. Tompkins Filed SC 13G/A on Augmedix, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • McKesson Ventures, LLC Filed SC 13D/A on Augmedix, Inc., latest Dec 16, 2022 (2 filings since Sep 15, 2022)
  • Augmedix, Inc. San Francisco, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Augmedix, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.2M4 Dec 31, 2023$7.9M4 Dec 31, 2022−8.8%
Accumulated depreciation$3.5M4 Dec 31, 2023$6.4M4 Dec 31, 2022−45.0%
Property and equipment, net$3.7M4 Dec 31, 2023$1.6M4 Dec 31, 2022+137.7%
Operating-lease assets (leased space)$5.2M4 Dec 31, 2023$1.6M4 Dec 31, 2022+233.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$46.2M4 Dec 31, 2023$21.3M4 Dec 31, 2022+117.5%

Leadership

Who has led Augmedix, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Emmanuel Krakaris2020–2024

President

  1. Emmanuel Krakaris2021–2024

Chief financial officer

  1. Paul Ginocchio2020–2024

Chief operating officer

  1. Sandra Breber2020–2024
2025
Board members and other officers (17)

Former names

  • Malo Holdings CorpMar 14, 2019 to Oct 1, 20202

Timeline

  1. Oct 2, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer31
  2. Sep 27, 20248-K Shareholder vote32
  3. Sep 16, 20248-K Other events33
  4. Aug 27, 20248-K Entered a material agreement34
  5. Aug 12, 20248-K Results of operations35
  6. Jul 19, 20248-K Entered a material agreement; Other events36
  7. Jun 26, 20248-K Entered a material agreement37
  8. Jun 25, 20248-K Regulation FD disclosure38
  9. Jun 25, 20248-K Regulation FD disclosure39
  10. Jun 5, 20248-K Regulation FD disclosure40
  11. May 13, 20248-K Results of operations41
  12. Apr 18, 20248-K Entered a material agreement42
  13. Oct 7, 2020New chief executive Emmanuel Krakaris becomes CEO12

Calendar

When it reported results

  1. Aug 12, 2024Reported quarterly or annual results35
  2. May 13, 2024Reported quarterly or annual results41
  3. Mar 18, 2024Reported quarterly or annual results43
  4. Jan 5, 2024Reported quarterly or annual results44
  5. Nov 6, 2023Reported quarterly or annual results45
  6. Aug 7, 2023Reported quarterly or annual results46
  7. May 12, 2023Reported quarterly or annual results47
  8. Mar 27, 2023Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

293 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 69 major events, 130 insider forms, 24 large holders, 1 private raises, 55 other. The latest 20:

  1. Nov 13, 2024SC 13G/A EDGAR
  2. Nov 13, 2024SC 13G/A EDGAR
  3. Oct 15, 202415-12G EDGAR
  4. Oct 4, 20244 EDGAR
  5. Oct 4, 20244 EDGAR
  6. Oct 4, 20244 EDGAR
  7. Oct 4, 20244 EDGAR
  8. Oct 4, 20244 EDGAR
  9. Oct 4, 20244 EDGAR
  10. Oct 4, 20244 EDGAR
  11. Oct 4, 20244 EDGAR
  12. Oct 4, 20244 EDGAR
  13. Oct 4, 20244 EDGAR
  14. Oct 4, 20244 EDGAR
  15. Oct 4, 20244 EDGAR
  16. Oct 4, 20244 OWNERSHIP DOCUMENT EDGAR
  17. Oct 4, 2024SC 13D/A EDGAR
  18. Oct 4, 20244 OWNERSHIP DOCUMENT EDGAR
  19. Oct 3, 2024EFFECT EDGAR
  20. Oct 3, 2024EFFECT EDGAR

The 293 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

56 open-market trades by officers, directors and large owners since October 2021: 23 buys and 33 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 15, 2024Ginocchio PaulCHIEF FINANCIAL OFFICERSale2,354$1.19$2.8KForm 4
May 15, 2024Chatterjee SauravCHIEF TECHNOLOGY OFFICERSale1,767$1.19$2.1KForm 4
May 15, 2024Shakil IanCHIEF STRATEGY OFFICERSale1,387$1.19$1.7KForm 4
May 15, 2024Krakaris EmmanuelPRESIDENT, CEO, AND SECRETARYSale3,528$1.19$4.2KForm 4
May 15, 2024Breber SandraCHIEF OPERATING OFFICERSale2,354$1.19$2.8KForm 4
May 15, 2024Hawkins JonathanCHIEF REVENUE OFFICERSale1,767$1.19$2.1KForm 4
Apr 15, 2024Shakil IanCHIEF STRATEGY OFFICERSale500$3.80$1.9KForm 4
Apr 12, 2024Shakil IanCHIEF STRATEGY OFFICERSale19,544$3.82$74.7KForm 4
Apr 11, 2024Shakil IanCHIEF STRATEGY OFFICERSale24,778$3.93$97.4KForm 4
Apr 10, 2024Shakil IanCHIEF STRATEGY OFFICERSale36,467$3.87$141.1KForm 4
Apr 9, 2024Shakil IanCHIEF STRATEGY OFFICERSale31,542$4.14$130.6KForm 4
Apr 8, 2024Shakil IanCHIEF STRATEGY OFFICERSale37,780$3.97$150.0KForm 4
Apr 5, 2024Shakil IanCHIEF STRATEGY OFFICERSale51,387$4.03$207.1KForm 4
Apr 4, 2024Shakil IanCHIEF STRATEGY OFFICERSale64,055$4.15$265.8KForm 4
Apr 3, 2024Shakil IanCHIEF STRATEGY OFFICERSale45,906$4.11$188.7KForm 4
Apr 2, 2024Shakil IanCHIEF STRATEGY OFFICERSale38,463$3.89$149.6KForm 4
Apr 1, 2024Shakil IanCHIEF STRATEGY OFFICERSale58,978$3.91$230.4KForm 4
Mar 28, 2024Shakil IanCHIEF STRATEGY OFFICERSale31,994$4.06$129.9KForm 4
Mar 28, 2024Shakil IanCHIEF STRATEGY OFFICERSale31,994$4.06$129.9KForm 4
Nov 22, 2023Ginocchio PaulCHIEF FINANCIAL OFFICERBuy10,000$4.85$48.5KForm 4

All 56 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$12.0M 2023–2023
Money received by yearMoney received by year, 2023–2023: $12.0M in all. Private raises (Form D) $12.0M.$0$5M$10M$15M2023 · Private raises (Form D): $12.0M2023
Figures by year
YearPrivate raises (Form D)Total
2023$12.0M$12.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Apr 19, 2023Raised $12 million in a private offering of equity55 Form D: 2 investors so far Form D

SEC filer profile

How Augmedix, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAugmedix, Inc.1
  • CIK0001769804
  • Employer ID (EIN)83-32991641
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)7389 Services-Business Services, NEC1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address111 Sutter Street, Suite 1300, San Francisco, CA 941041
  • Phone561-989-22081
  • Shares outstanding49,243,752 as of Aug 7, 20249
  • Public float$117.0M as of Jun 30, 202356
  • On EDGAR sinceMar 14, 20191
  • Filings392 in all: 4 (144), 8-K (85), 3 (24), SC 13D/A (18), 10-Q (17), DEFA14A (8), EFFECT (8), CORRESP (6)1
    All 43 form types

    UPLOAD (6), 10-K (5), 424B3 (4), 8-K/A (4), POS AM (4), S-8 (4), S-8 POS (4), SC 13G/A (4), 10-K/A (3), 4/A (3), 424B5 (3), D (3), DEF 14A (3), S-3 (3), SC 13D (3), SC 13G (3), 144 (2), S-1 (2), S-1/A (2), SEC STAFF LETTER (2), 10-12G (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DEFM14A (1), NT 10-K (1), NT 10-Q (1), PRE 14A (1), PREM14A (1), RW (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2024
    Quarterly report (10-Q) Aug 12, 2024
    Proxy statement (DEF 14A) Jun 26, 2023
    Latest 8-K (8-K) Oct 2, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56